Rachel Wong

The Royal Marsden NHS Foundation Trust, Londinium, England, United Kingdom

Are you Rachel Wong?

Claim your profile

Publications (4)32.23 Total impact

  • Source
    Gut 06/2011; 60(11):1449-72. · 10.73 Impact Factor
  • Rachel Wong, David Cunningham
    Journal of Clinical Oncology 12/2008; 26(35):5668-70. · 18.04 Impact Factor
  • Rachel Wong, David Cunningham
    [Show abstract] [Hide abstract]
    ABSTRACT: An impressive array of therapeutic biological agents is currently being studied in the treatment of colorectal and other cancers. In advanced colorectal cancer, the majority of evidence currently available supporting the use of biological agents outside clinical trials involves the monoclonal antibodies cetuximab and panitumumab, which are epidermal growth factor receptor (EGFR) inhibitors, and the vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab. Ongoing studies are underway to see if benefits are transferable into the adjuvant setting. The role of small molecules that inhibit the EGFR and VEGF receptors in colorectal cancer is yet to be determined. This article reviews the current clinical evidence regarding the use of biological agents in colorectal cancer and the potential impact on day-to-day management of this common clinical condition.
    Targeted Oncology 01/2008; 3(2):59-69. · 3.46 Impact Factor
  • Rachel Wong, David Cunningham, Ian Chua
    [Show abstract] [Hide abstract]
    ABSTRACT: There are many unanswered questions regarding the role of adjuvant chemotherapy in rectal cancer. The advent of total mesorectal excision (TME) and the use of radiation therapy, either alone or in combination with chemotherapy, have resulted in improved local recurrence rates. Alongside, these treatment advances have been improvements in the ability to accurately stage rectal cancer with imaging modalities such as endorectal ultrasound (ERUS) and magnetic resonance imaging (MRI). Despite progress in these areas, for many patients with rectal cancer, particularly those with high-risk rectal cancer, long-term survival outcomes remain poor, predominantly due a high frequency of systemic failure. For early-stage disease, it is hoped that administering systemic treatment will eradicate micrometastases and therefore reduce the incidence of distant relapse. We, herein, evaluate the current evidence for adjuvant chemotherapy and the potential role of the novel strategy of neoadjuvant chemotherapy in the treatment of rectal cancer.